GSK plc
Bear Case (25th pct.)
7.7% vs price
Base Case (Median)
10.7% vs price
Bull Case (75th pct.)
44.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $53.10 | 100.4% | High (40%) |
| PE Comparable | $29.17 | 10.1% | Medium (25%) |
| Growth Trajectory DCF | $44.33 | 67.3% | Medium (20%) |
| Graham Number | $10.92 | -58.8% | Medium (40%) |
| EV/EBITDA | $29.33 | 10.7% | Medium (20%) |
| EV/FCF | $27.92 | 5.4% | Medium (20%) |
| Earnings Power Value | $32.08 | 21.1% | Medium (50%) |
Based on 7 out of 8 methods, GLAXF appears undervalued at the current price of $26.50. The base case fair value of $29.33 implies 10.7% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.